Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German low-grade lymphoma study group

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1922-1930

  Hiddemann, Wolfgang ^a   Unterhalt, Michael ^a   Herrmann, Richard ^a   Wöltjen, Hans Heinrich ^a   Kreuser, Ernst Dietrich ^a   Trümper, Lorenz ^a   Reuss Borst, Monika ^a   Terhardt Kasten, Elke ^a   Busch, Mechthild ^a   Neubauer, Andreas ^a   Kaiser, Ulrich ^a   Hanrath, Rolf Dieter ^a   Middeke, Helmut ^a   Helm, Gisela ^a   Freund, Mathias ^a   Stein, Harald ^a   Tiemann, Markus ^a   Parwaresch, Reza ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031804013     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1922     Document Type: Article

References (34)

1. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
2. Lennert K, Stein H, Kaiserling E: Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 31:29-43, 1975 (suppl 2)
3. Lennert K, Feller A: Histopathology of Non-Hodgkin's Lymphomas (ed 2). Berlin, Heidelberg, New York, Springer-Verlag, 1992
4. Medeiros LJ, Van Krieken JH, Jaffe ES, et al: Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 76:2086-2090, 1990
5. Rosenberg CL, Wong E, Petty EM, et al: PRAD1, a candidate bcl-1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 88:9638-9642, 1991
6. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bcl-1 linked candidate oncogene. Nature 350:512-515, 1991
7. Williams ME, Swerdlow SH, Rosenberg CL, et al: Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. Leukemia 7:241-245, 1993
8. Rimokh R, Berger F, Delsol G, et al: Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood 81:2063-2067, 1993
9. Swerdlow SH, Yang WI, Zukerberg LR, et al: Expression of cyclin D1 protein in centrocytic/mantle cell lymphomas with and without rearrangement of the Bcl-1/cyclin D1 gene. Hum Pathol 26:999-1004, 1995
10. De Boer CJ, Schuuring E, Dreef E, et al: Cyclin D1 protein analysis in the diagnosis of mantle cell lymphomas. Blood 86:2715-2723, 1995
11. Bérard CW, Dorfman RF: Histopathology of malignant lymphoma. Clin Haematol 3:39-76, 1974
12. Nanba K, Jaffe ES, Braylan RS, et al: Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. Am J Clin Pathol 68:535-542, 1977
13. Weisenburger DD, Kim H, Rappaport H: Mantle-zone lymphoma: A follicular variant of intermediate lymphocytic lymphoma. Cancer 49:1429-1438, 1982
14. Weisenburger DD: Mantle cell lymphoma, in Knowles DM (ed): Neoplastic Hematopathology. Baltimore, MD, Williams & Wilkins, 1992, pp 617-628
15. Banks PM, Chan J, Cleary ML, et al: Mantle cell lymphoma, a proposal for unification of morphologic, immunologic and molecular data. Am J Surg Pathol 607:637-640, 1992
16. Raffeld M, Jaffe ES: Bel-1, t(11;14) and mantle cell-derived lymphomas. Blood 78:259-263, 1991
17. Zucca E, Stein H, Coiffier B: European lymphoma task force (ELTF): Report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 5:507-511, 1994
18. Meusers P, Engelhard M, Bartels H, et al: Multicenter randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
19. Zucca E, Roggero E, Pinotii G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
20. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249-256, 1995
21. Fisher RI, Dahlberg S, Bharat NN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytic B-cell subcategories): A Southwest Oncology Group Study. Blood 85:1075-1082, 1995
22. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al: Efficacy of four different regimens in 64 mantle cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 13:2819-2826, 1995
23. Velders GA, Kluin-Nelemans JC, de Boer CJ, et al: Mantle cell lymphoma: A population-based clinical study. J Clin Oncol 14:1269-1274, 1996
24. Hiddemann W, Unterhalt M: New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: Prednimustine/ mitoxantrone (PmM) vs cyclophosphamide/vincristine/prednisone (COP) followed by interferon vs observation only - A preliminary update of the German Low-Grade Lymphoma Study Group. Semin Hematol 31:32-35, 1994 (suppl 3)
25. Unterhalt M, Herrmann R, Tiemann M, et al: Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. Leukemia 10:836-843, 1996
26. Unterhalt M, Herrmann R, Nahler M, et al: Significant prolongation of disease-free survival in advanced low-grade non-Hodgkin's lymphomas (NHL) by interferon alfa maintenance. Blood 86:439A, 1995 (suppl. 1, abstr)
27. Weisenburger DD, Nathwani BN, Diamond LW, et al: Malignant lymphoma, intermediate lymphocytic type: A clinico-pathologic study of 42 cases. Cancer 48:1415-1425, 1981
28. Swerdlow SH, Habeshaw JA, Muray LJ, et al: Centrocytic lymphoma: A distinct clinicopathologic and morphologic entity, a multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol 113:181-197, 1983
29. Brittinger G, Bartels H, Common H, et al: Clinical and prognostic relevance of the Kiel classification of non-Hodgkin's lymphomas. Result of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2:269-306, 1984
30. Richards MA, Hall PA, Gregory WM, et al: Lymphoplasmacytoid and small-cell centrocytic non-Hodgkin's lymphoma: A retrospective analysis from St Bartholomew's Hospital 1972-1989. Hematol Oncol 7:19-35, 1989
31. Ott MM, Ott G, Kuse R, et al: The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology 24:329-334, 1994
32. Vose JM, Weisenburger DD, Anderson JR, et al: Mantle cell lymphoma (MCL) has a poorer prognosis than follicular non-Hodgkin's lymphoma (F-NHL); However, high-dose therapy (HDC) and autologous stem cell transplantation (ASCT) may overcome treatment resistance in MCL. Blood 82:135A, 1993 (suppl. 1, abstr)
33. Stewart DA, Vose JM, Weisenburger DD, et al: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 6:263-266, 1995
34. Sessa C, Zucchetti M, Cerny T, et al: Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J Clin Oncol 13:200-209, 1995